AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the ...

The extent and manner in which these networks interact during lateralized movement remains unclear. In this study, simultaneously recorded bilateral Globus Pallidus interna (GPi) local field ...

Morgan Stanley analyst Kallum Titchmarsh maintained a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of $100.00. The company’s shares closed yesterday at ...

Globus Medical stock opened at $80.00 on Tuesday. Globus Medical, Inc. has a one year low of $49.33 and a one year high of $94.93. The company’s fifty day moving average price is $86.68 and its ...

Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The company had revenue of $657.29 million for the quarter, compared to the consensus estimate of $646.19 million.

Welcome to the Globus Medical's fourth quarter and full year 2024 earnings call. At this time, all lines will be on mute, and a Q&A session will be held after the prepared remarks. I will now turn ...

Globus finished 2024 with a great fourth quarter ... Cortex MIS is integrated with our advanced Excelsius technology and designed for accurate screw placement using a minimally invasive robotic ...

Scavilla announced the acquisition of Nevro Corporation for $250 million, aimed at expanding Globus' reach into the $2 billion neuromodulation market. He stated, "Nevro technology offers ...